CY 6033
Symptomatic Non-Obstructive Hypertrophic CardiomyopathyThere is currently no effective medical therapy for nHCM. Aficamten is an oral investigational drug designed to reduce excessive contraction of your heart muscle that is the root cause of nHCM.
This study is designed to further evaluate the effect of aficamten on quality of life, exercise capacity, heart failure symptoms, cardiac biomarkers, cardiac remodeling, and clinical outcomes. Additionally, the safety and tolerability of aficamten will be assessed in participants with nHCM.
null
Participation Requirements
-
Sex:
Female, Male -
Eligible Ages:
18 to 85
Participation Criteria
Inclusion Criteria:
1. Between 18–85 years of age at screening
2. Body mass index <40 kg/m2
3. Diagnosed with nHCM and has a screening echocardiogram
Exclusion Criteria:
1. Significant valvular heart disease (per Investigator judgment)
2. Known or suspected infiltrative, genetic or storage disorder causing cardiac hypertrophy that mimics nHCM (e.g., Noonan syndrome, Fabry disease, amyloidosis)
3. Known current unrevascularized coronary artery stenosis of ≥ 70% or documented history of myocardial infarction.
Study Location
University of Alberta
University of AlbertaEdmonton, Alberta
Canada
Contact Study Team
- Study Sponsored By
- University of Alberta
- Participants Required
- More Information
- Study ID:
Pro00142347